Table 1 Clinical characteristics of the patients in the RNA sequencing cohort

Age (years), median [Q1, Q3]

49.0 [46.0, 53.0]

43.5 [37.8, 53.0]

49.0 [31.0, 50.8]

Female (%)

1 (11.1)

3 (25.0)

2 (16.7)

Male (%)

8 (88.9)

9 (75.0)

10 (83.3)

HBV DNA level (IU/ml)

≤ 2 × 10^2

9

11

–

2 × 10^2–2 × 10^6

0

1

–

> 2 × 10^6

0

0

–

Antiviral therapy (%)

9 (100)

11 (91.7)

–

Laboratory data, mean (SD)

Albumin (g/L)

46.6 (3.1)

49.7 (2.4)

48.8 (2.5)

Globulin (g/L)

26.6 (2.1)

27.3 (1.6)

25.6 (3.3)

Total bilirubin (µmol/L)

15.4 (4.2)**

16.2 (6.6)*

10.5 (2.1)

Direct bilirubin (µmol/L)

5.8 (1.9)**

5.8 (2.3)**

3.3 (0.7)

Indirect bilirubin (µmol/L)

9.7 (2.8)*

10.4 (4.8)*

7.2 (1.7)

Alanine aminotransferase (U/L)

20.1 (9.9)

31.0 (16.1)

24.3 (16.3)

Aspartate aminotransferase (U/L)

23.2 (4.9)

25.4 (7.9)

22.4 (7.4)

Alkaline phosphatase (U/L)

95.3 (42.9)

81.8 (29.4)

66.0 (24.6)

γ-Glutamyl transpeptidase (U/L)

32.4 (19.4)

27.2 (18.4)

29.6 (20.9)

Total bile acid (µmol/L)

9.0 (8.3)

5.2 (3.7)

4.6 (2.2)

Triglyceride (mmol/L)

1.3 (0.8)

1.2 (0.7)

1.5 (0.7)

Total cholesterol (mmol/L)

3.8 (0.4)**

3.9 (0.9)*

4.6 (0.5)

Creatinine (µmol/L)

71.2 (11.0)

72.8 (18.9)

80.8 (9.1)

Blood urea nitrogen (mmol/L)

6.1 (1.8)

4.8 (0.8)

4.9 (1.1)

K⁺ (mmol/L)

4.4 (0.3)

4.2 (0.3)

4.3 (0.6)

Na⁺ (mmol/L)

141.5 (2.6)

142.1 (2.4)

142.0 (2.8)

INR

1.0 (0.2)

1.0 (0.1)

–

White blood cells (*10^9/L)

4.9 (1.5)

5.5 (0.9)

6.4 (0.8)

Hemoglobin (g/L)

154.4 (10.8)

154.9 (14.1)

149.8 (16.8)

Platelets (*10^12/L)

149.2 (100.2)*

169.0 (66.8)*

238.6 (42.9)